The Association of Post-Stroke Cognitive Impairment and Gut Microbiota and its Corresponding Metabolites

Liu, Yongqiang; Kong, Cheng; Gong, Li; Zhang, Xiaohui; Zhu, Yuefei; Wang, Haichao; Qu, Xiao; Gao, Renyuan; Yin, Fang; Liu, Xueyuan; Qin, Huanlong

doi:10.3233/jad-191066

Cited by 67 publications

(44 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A case‐control study with a small sample size, conducted in Japan, found decreased acetic acid and increased valeric acid levels in patients with ischemic stroke 6 . In addition, increased Fusobacterium and deficiency of SCFAs were observed in poststroke cognitive impairment patients, and probiotic administration relieved depression and anxiety 20 . In this study, we found an increased F/B ratio, a lack of SCFA‐producing bacteria and SCFAs, and a disrupted intestinal barrier in AIS patients.…”

Section: Discussionsupporting

confidence: 51%

Dysbiosis of Gut Microbiota and Short‐Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes

Tan

Wang

et al. 2020

J Parenter Enteral Nutr

118

111

View full text Add to dashboard Cite

Background The intestinal microbiota and its metabolites have been reported to play an important role in stroke. Gut microbiota–originating short‐chain fatty acids (SCFAs) modulate brain functions directly or indirectly through immune, endocrine, vagal, and other humoral pathways. However, relatively few investigations have evaluated the gut microbiome and SCFAs spectrum or their potential associations with stroke outcomes in acute ischemic stroke (AIS) patients with different stroke severities. Methods We used 16S rRNA gene sequencing and gas chromatography to compare the fecal microbial composition and SCFA spectrum between AIS patients (n = 140) and healthy controls (n = 92). Their associations with 90‐day poor functional outcomes were evaluated by logistic regression models. Results We found that the intestinal microbiota distinguished AIS patients from healthy controls. A lack of SCFAs‐producing bacteria and a low fecal SCFAs level defined dysbiosis in AIS patients, especially those with increased stroke severity. The SCFAs levels were negatively correlated with stroke severity and prognosis. Reduced SCFAs levels, especially acetate, were associated with an increased risk of 90‐day poor functional outcomes even after adjustments. Conclusions Dysbiosis of SCFAs‐producing bacteria and SCFAs in AIS patients increased the subsequent risk for poor functional outcomes, indicating that SCFAs could be potential prognostic markers and therapeutic targets for stroke.

show abstract

Section: Discussionsupporting

confidence: 51%

Dysbiosis of Gut Microbiota and Short‐Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes

Tan

Wang

et al. 2020

J Parenter Enteral Nutr

118

111

View full text Add to dashboard Cite

show abstract

“…Beta-sitosterol and stigmasterol are the common components of Carthami flos , Persicae Semen , Radix Paeoniae Rubra , and Angelicae sinensis Radix . They are both sterol compounds, mainly having the functions of reducing blood fat, antioxidation, and anti-inflammation [ 56 ].…”

Section: Discussionmentioning

confidence: 99%

Network Pharmacology and Molecular Docking Analysis on Molecular Targets and Mechanisms of Buyang Huanwu Decoction in the Treatment of Ischemic Stroke

Gao

Tian

Han

et al. 2021

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Background and Objective. With the exact clinical efficacy, Buyang Huanwu decoction (BHD) is a classical prescription for the treatment of ischemic stroke (IS). Here, we aimed to investigate the pharmacological mechanisms of BHD in treating IS using systems biology approaches. Methods. The bioactive components and potential targets of BHD were screened by TCMSP, BATMAN-TCM, ETCM, and SymMap databases. Besides, compounds that failed to find the targets from the above databases were predicted through STITCH, SwissTargetPrediction, and SEA. Moreover, six databases were searched to mine targets of IS. The intersection targets were obtained and analyzed by GO and KEGG enrichment. Furthermore, BHD-IS PPI network, compound-target network, and herb-target-pathway network were constructed by Cytoscape 3.6.0. Finally, AutoDock was used for molecular docking verification. Results. A total of 235 putative targets were obtained from 59 active compounds in BHD. Among them, 62 targets were related to IS. PPI network showed that the top ten key targets were IL6, TNF, VEGFA, AKT1, etc. The enrichment analysis demonstrated candidate BHD targets were more frequently involved in TNF, PI3K-Akt, and NF-kappa B signaling pathway. Network topology analysis showed that Radix Astragali was the main herb in BHD, and the key components were quercetin, beta-sitosterol, kaempferol, stigmasterol, etc. The results of molecular docking showed the active components in BHD had a good binding ability with the key targets. Conclusions. Our study demonstrated that BHD exerted the effect of treating IS by regulating multitargets and multichannels with multicomponents through the method of network pharmacology and molecular docking.

show abstract

“…The discrepancy of PSCI incidence may be mainly attributed to differences in race, age, educational status, diagnostic criteria, and study methods. Most studies have assessed cognitive function at 3 months after a stroke using cross-sectional design [21][22][23][24][25], whereas some studies have adopted longitudinal designs [3,26]. Several diagnostic tools have been applied to investigate the presence of PSCI, such as National Institute of Neurological Disorders and Stroke and Canadian Stroke Network (NINDS-CSN), Mini-Mental State Examination (MMSE), and MoCA.…”

Section: Discussionmentioning

confidence: 99%

“…According to previous studies [18,20,21], a total MoCA score < 25 was diagnosed as PSCI. Also, the degree of cognitive impairment was categorized as follows: severe cognitive impairment (MoCA score, 0-19), mild cognitive impairment (MoCA score, [20][21][22][23][24], and no cognitive impairment (MoCA score, [25][26][27][28][29][30] [20].…”

Section: Cognitive Evaluationmentioning

confidence: 99%

Serum Periostin and Cognitive Impairment in Ischemic Stroke Patients: a Prospective Cohort Study

Zhu

et al. 2021

Preprint

View full text Add to dashboard Cite

Background. Recent evidence suggest elevated periostin is associated with cardiovascular diseases. The aim of this study was to investigate the relationship between serum periostin and post-stroke cognitive impairment (PSCI) at 3 months. Methods. In this prospective cohort study, we enrolled patients with ischemic stroke and hospitalized within 7 days of symptoms onset from January 2019 to January 2020. Serum periostin levels were measured using enzyme-linked immunosorbent assay after admission. Cognitive function assessment was performed at 3-month follow-up visit using the Montreal Cognitive Assessment (MoCA). We defined the PSCI as total MoCA score < 25. Results. A total of 315 ischemic stroke patients were enrolled for the study. PSCI was observed in 173 patients, which accounted for 54.9% (95% confidence interval [CI] 52.1%–57.7%) of the cohort. Serum periostin levels were higher in patients with PSCI than in those without PSCI (median 19.6 vs 14.8 ng/mL; P = 0.001). In logistic regression analysis, the highest quartile of periostin levels were significantly correlated to PSCI (odds ratio [OR], 9.69; 95% CI, 5.06–25.61; P = 0.001), as compared with the lowest quartile. This association remained significant after adjustment for age, gender, educational years, stroke severity, and vascular risk factors. Subgroup analyses further confirmed these results. Furthermore, restricted cubic spline regression demonstrated a linear association between periostin levels and PSCI (P = 0.001 for linearity).Conclusions. This study found that higher serum periostin levels are associated with an increased risk of PSCI at 3 months after ischemic stroke onset.

show abstract

The Association of Post-Stroke Cognitive Impairment and Gut Microbiota and its Corresponding Metabolites

Cited by 67 publications

References 44 publications

Dysbiosis of Gut Microbiota and Short‐Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes

Dysbiosis of Gut Microbiota and Short‐Chain Fatty Acids in Acute Ischemic Stroke and the Subsequent Risk for Poor Functional Outcomes

Network Pharmacology and Molecular Docking Analysis on Molecular Targets and Mechanisms of Buyang Huanwu Decoction in the Treatment of Ischemic Stroke

Serum Periostin and Cognitive Impairment in Ischemic Stroke Patients: a Prospective Cohort Study

Contact Info

Product

Resources

About